Headquartered in Foster City, CA·Fiscal year ends December·NASDAQ: GERN·geron.com
About Geron
Geron Corporation is a commercial-stage biopharmaceutical company focused on hematology and blood cancers, built on expertise in telomerase biology.
Its sole marketed medicine is RYTELO (imetelstat), a first-in-class oligonucleotide telomerase inhibitor. RYTELO is approved in the U.S. for adults with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. It is approved in the European Union for transfusion-dependent anemia in very low, low or intermediate risk non-del 5q MDS. Treatment is given as a two-hour intravenous infusion every four weeks.
Revenue comes almost entirely from U.S. net product sales of RYTELO through about 1,700 ordering accounts, with community practices driving demand growth. A small amount of royalty income is also recorded. Geron has begun a gated commercial launch in targeted European markets, with availability expected in Germany by end of 2026 and in France in 2027.
After discontinuing the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, the company is concentrated on LR-MDS. Ongoing activity includes investigator-sponsored and real-world evidence studies on mechanism, combinations, sequencing and earlier-line use. Geron is funded by cash and marketable securities, product revenue, and debt and synthetic royalty financing arrangements. Updated
The top analyst upgrades, downgrades and initiations for Tuesday included Annaly Capital Management, Amazon.com, Enterprise Products Partners, Kinder Morgan, Lululemon Athletica, RealReal, Snap, Square and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Anadarko Petroleum, Apple, Charter Communications, Geron, KLA-Tencor, PVH, SAP, Walt Disney and United States Steel.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Activision Blizzard, Biogen, Deere, DocuSign, Ford, Freeport-McMoRan, General Motors, Lattice Semiconductor, Qualys, Shopify and Under Armour.
Judging by the most shorted stocks traded on the Nasdaq between the September 14 and September 28 settlement dates, those sellers were looking for direction.
Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.
Judging by the most shorted stocks traded on the Nasdaq between the August 31 and September 14 settlement dates, those sellers were focused on Qualcomm.
Judging by the most shorted stocks traded on the Nasdaq between the August 15 and August 31 settlement dates, those sellers may have been looking for direction.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 13 and July 31 settlement dates, those sellers were looking for direction, as moves in their favorites were mixed…
Judging by the most shorted stocks traded on the Nasdaq between the June 29 and July 13 settlement dates, those sellers were cautious, as their favorites saw shrinking or flat short interest.
Judging by the most shorted stocks traded on the Nasdaq between the June 15 and June 29 settlement dates, those sellers were focused on a few of favorites.
The top analyst upgrades, downgrades and other research calls from Thursday include Allergan, Cheniere Energy, Clean Energy, Facebook, Fiat Chrysler, Intel and NetApp.
Geron Corporation is a commercial-stage biopharmaceutical company focused on hematology and blood cancers, built on expertise in telomerase biology. Its sole marketed medicine is RYTELO (imetelstat), a first-in-class oligonucleotide telomerase inhibitor.
What is the GERN stock price target?
The Wall Street consensus 12-month price target for GERN is $3.50.